Immunostaining of adaptor proteins in human lymphoid neoplasms
Neoplasm . | LAT . | LIME . | TRIM . | NTAL . | PAG . | SIT . |
|---|---|---|---|---|---|---|
| B cell | ||||||
| Lymphoblastic lymphoma/leukemia | 0/2 | 0/2 | 0/2 | 1/2 | 2/2 | 0/2 |
| Chronic lymphocytic leukemia/lymphoma | 0/16 | 0/19 | 0/19 | 7a/18 | 0/19 | 18/19 |
| Mantle-cell lymphoma | 0/17 | 2b/19 | 0/19 | 2/19 | 1/19 | 16/19 |
| Follicle-center lymphoma | ||||||
| Grade I | 0/25 | 0/25 | 0/25 | 23/25 | 25/25 | 3/25 |
| Grade II | 0/20 | 0/22 | 0/21 | 20/22 | 22/22 | 2/20 |
| Grade III | 0/57 | 0/53 | 0/58 | 40/56c | 43/58d | 6/57 |
| Burkitt lymphoma | 0/9 | 0/11 | 0/11 | 4/10 | 8/11 | 5/11 |
| Diffuse large B-cell lymphoma | 0/57 | 0/60 | 0/60 | 36/60 | 28/61 | 6/60 |
| Primary mediastinal B-cell lymphoma | 0/12 | 0/12 | 0/13 | 8/8 | 5/13 | 1/12 |
| T-cell–rich B-cell lymphoma | 0/7 | 0/15 | 0/14 | 8e/15 | 1/15 | 0/15 |
| Marginal-zone lymphoma | ||||||
| Nodal | 0/6 | 0/6 | 0/6 | 5/6 | 2/6 | 4/6 |
| Splenic | 0/19 | 0/18 | 0/19 | 9f/19 | 3/19 | 14g/16 |
| MALT lymphoma | 0/6 | 0/6 | 0/5 | 6/11 | 7/11 | 5/11 |
| Lymphoplasmacytic lymphoma | 0/2 | 1/3 | 0/3 | 1/2 | 0/3 | 0/3 |
| Hairy-cell leukemia | 0/5 | 0/5 | 0/5 | 5/5 | 0/4 | 0/5 |
| Myeloma/plasmacytoma | 0/11 | 9/12 | 3/12 | 7h/13 | 2i/12 | 11j/13 |
| Posttransplantation lymphoproliferative disorder | 0/3 | 0/3 | 0/3 | 2/2 | 1/2 | 0/3 |
| T cell | ||||||
| Lymphoblastic lymphoma/leukemia | 6/12 | 8/11 | 11/12 | 5/11 | 9/11 | 3/12 |
| Peripheral T-cell lymphoma (NOS) | 12/13 | 7/13 | 6/12 | 0/13 | 7/13 | 2/12 |
| Angioimmunoblastic T-cell lymphoma (AILT) | 4/4 | 3/3 | 3/3 | 0/4 | 3/4 | 0/4 |
| Enteropathy-type T-cell lymphoma | 3/3 | 0/2 | 3/3 | 0/3 | 0/3 | 0/3 |
| NK-cell lymphoma | 3/4 | 2/3 | 1/3 | 0/3 | 3/4 | 0/3 |
| ALK+ lymphoma | 6/11 | 0/5 | 0/5 | 2/10 | 5/13 | 0/12 |
| Hodgkin disease | ||||||
| Classic | 0/36 | 0/38 | 0/35 | 4/39k | 0/39k | 0/36l |
| Lymphocyte predominant | 0/11 | 0/19 | 0/19 | 13/19m | 2/19 | 0/19 |
Neoplasm . | LAT . | LIME . | TRIM . | NTAL . | PAG . | SIT . |
|---|---|---|---|---|---|---|
| B cell | ||||||
| Lymphoblastic lymphoma/leukemia | 0/2 | 0/2 | 0/2 | 1/2 | 2/2 | 0/2 |
| Chronic lymphocytic leukemia/lymphoma | 0/16 | 0/19 | 0/19 | 7a/18 | 0/19 | 18/19 |
| Mantle-cell lymphoma | 0/17 | 2b/19 | 0/19 | 2/19 | 1/19 | 16/19 |
| Follicle-center lymphoma | ||||||
| Grade I | 0/25 | 0/25 | 0/25 | 23/25 | 25/25 | 3/25 |
| Grade II | 0/20 | 0/22 | 0/21 | 20/22 | 22/22 | 2/20 |
| Grade III | 0/57 | 0/53 | 0/58 | 40/56c | 43/58d | 6/57 |
| Burkitt lymphoma | 0/9 | 0/11 | 0/11 | 4/10 | 8/11 | 5/11 |
| Diffuse large B-cell lymphoma | 0/57 | 0/60 | 0/60 | 36/60 | 28/61 | 6/60 |
| Primary mediastinal B-cell lymphoma | 0/12 | 0/12 | 0/13 | 8/8 | 5/13 | 1/12 |
| T-cell–rich B-cell lymphoma | 0/7 | 0/15 | 0/14 | 8e/15 | 1/15 | 0/15 |
| Marginal-zone lymphoma | ||||||
| Nodal | 0/6 | 0/6 | 0/6 | 5/6 | 2/6 | 4/6 |
| Splenic | 0/19 | 0/18 | 0/19 | 9f/19 | 3/19 | 14g/16 |
| MALT lymphoma | 0/6 | 0/6 | 0/5 | 6/11 | 7/11 | 5/11 |
| Lymphoplasmacytic lymphoma | 0/2 | 1/3 | 0/3 | 1/2 | 0/3 | 0/3 |
| Hairy-cell leukemia | 0/5 | 0/5 | 0/5 | 5/5 | 0/4 | 0/5 |
| Myeloma/plasmacytoma | 0/11 | 9/12 | 3/12 | 7h/13 | 2i/12 | 11j/13 |
| Posttransplantation lymphoproliferative disorder | 0/3 | 0/3 | 0/3 | 2/2 | 1/2 | 0/3 |
| T cell | ||||||
| Lymphoblastic lymphoma/leukemia | 6/12 | 8/11 | 11/12 | 5/11 | 9/11 | 3/12 |
| Peripheral T-cell lymphoma (NOS) | 12/13 | 7/13 | 6/12 | 0/13 | 7/13 | 2/12 |
| Angioimmunoblastic T-cell lymphoma (AILT) | 4/4 | 3/3 | 3/3 | 0/4 | 3/4 | 0/4 |
| Enteropathy-type T-cell lymphoma | 3/3 | 0/2 | 3/3 | 0/3 | 0/3 | 0/3 |
| NK-cell lymphoma | 3/4 | 2/3 | 1/3 | 0/3 | 3/4 | 0/3 |
| ALK+ lymphoma | 6/11 | 0/5 | 0/5 | 2/10 | 5/13 | 0/12 |
| Hodgkin disease | ||||||
| Classic | 0/36 | 0/38 | 0/35 | 4/39k | 0/39k | 0/36l |
| Lymphocyte predominant | 0/11 | 0/19 | 0/19 | 13/19m | 2/19 | 0/19 |
The number of positive cases per the total number is reported in the table.
NOS indicates not otherwise specified.
In 5 of the 7 cases the intensity of the staining was weak to moderate; only 2 cases showed a strong reaction
The intensity of the staining was very weak
In 6 cases less than 50% of tumor cells were positive
In 4 cases less than 50% of tumor cells were positive
In 2 of the 8 cases, only a proportion of tumor cells (50% in one case and 5% in the other) were positive
Three out of 9 cases showed very weak NTAL positivity
Seven of the 14 cases were weakly positive for SIT
In 2 cases only weak focal positivity was observed
In the 2 cases only focal positivity was observed
In 2 cases only weak focal positivity was found
In 3 cases only single tumor cells were positive
Two cases showed less than 50% and single positive tumor cells, respectively
In 2 cases single tumor cells were positive